Cystinuria Clinical Trial
Official title:
Randomized, Controlled and Opened Trial on the Impact of the Use of a pH-Meter on the Domiciliary Control of the Urinary pH as Adjuvant to the Treatment of Cystinuric Patients
This study evaluates the superiority of daily self-pH monitorization of Lit-control®pH meter compared to the monitorization of reactive strips (standard of care).
Cystinuria is a disease of autosomal recessive inheritance. This disease belongs to the
so-called orphan diseases although its prevalence may change depending on the country.
It is known that urinary pH is a risk factor for the formation of cystine crystals because
their solubility is pH-dependent. In different studies it has been shown that the solubility
of cystine in urine increases when alkalinizing urinary pH, thus reducing the likelihood of
crystal formation. Therefore, the control of urinary pH along with hygienic-dietetic measures
that alkalize the urine or decrease the urinary concentration of cystine (abundant intake of
water, food, etc.) are highly recommended as a preventive method to prevent the formation of
cystine crystals whose retention and growth results in the formation of stones.
The Lit-control®pH Meter is a pH meter that allows a patient to self-monitor its urinary pH
in a comfortable and simple way. With this tool the patient is able to know if his urinary pH
is within the recommended limits. In other medical fields it has been observed that home
monitoring of clinically relevant physiological parameters is a way of empowering the patient
that can positively affect their attitudes and behaviors (adherence to received treatment,
quality of life) and potentially improve their medical condition. Specifically, in patients
with chronic diseases, the self-monitoring has been associated with a significant reduction
in hospitalizations and hospital readmissions.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02120105 -
Cystine Capacity Clinical Study (CysCap)
|
||
| Completed |
NCT02538016 -
TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study
|
N/A | |
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Recruiting |
NCT00169806 -
Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis
|
N/A | |
| Completed |
NCT03663855 -
Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria
|
Phase 2 | |
| Recruiting |
NCT02780297 -
Prospective Research Rare Kidney Stones (ProRKS)
|
||
| Recruiting |
NCT02026388 -
Rare Kidney Stone Consortium Biobank
|
||
| Recruiting |
NCT04818034 -
The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study
|
Phase 2 | |
| Withdrawn |
NCT04137978 -
Study Evaluating Patients With Cystinuria
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02942420 -
Bucillamine Phase 2 Trial in Patients With Cystinuria
|
Phase 2 | |
| Completed |
NCT05048563 -
Registry of Thiola EC Therapy
|
||
| Not yet recruiting |
NCT04147871 -
Study Evaluating Patients With Cystinuria and Efficacy and Safety Exploratory Study in the Youngest Children
|
Phase 2/Phase 3 | |
| Completed |
NCT02125721 -
Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria
|
Phase 4 | |
| Active, not recruiting |
NCT02910531 -
Lipoic Acid Supplement for Cystine Stone
|
Phase 2 | |
| Recruiting |
NCT00588562 -
Rare Kidney Stone Consortium Patient Registry
|
||
| Completed |
NCT02124395 -
Health-related Quality of Life in Rare Kidney Stone
|
||
| Not yet recruiting |
NCT05058859 -
Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in Cystinurics
|
Phase 2 | |
| Completed |
NCT00381849 -
Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones
|
Phase 1/Phase 2 | |
| Completed |
NCT03836144 -
Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria
|